Precision BioSciences’ (DTIL) “Buy” Rating Reaffirmed at HC Wainwright

Precision BioSciences (NASDAQ:DTIL)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $60.00 target price on the stock.

Separately, BMO Capital Markets raised shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective on the stock in a research note on Friday, January 10th.

Precision BioSciences Stock Down 1.0 %

Precision BioSciences stock traded down $0.05 on Wednesday, hitting $4.93. 27,344 shares of the stock traded hands, compared to its average volume of 169,213. Precision BioSciences has a 1 year low of $3.61 and a 1 year high of $15.97. The firm has a market cap of $37.82 million, a P/E ratio of 82.51 and a beta of 1.59. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. The business’s fifty day simple moving average is $5.12 and its 200 day simple moving average is $6.79.

Insiders Place Their Bets

In related news, CEO Michael Amoroso sold 36,838 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total transaction of $172,033.46. Following the sale, the chief executive officer now directly owns 107,087 shares of the company’s stock, valued at approximately $500,096.29. This represents a 25.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider J. Jefferson Smith sold 10,287 shares of Precision BioSciences stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total transaction of $49,274.73. Following the completion of the transaction, the insider now directly owns 87,440 shares of the company’s stock, valued at $418,837.60. This trade represents a 10.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 8,734 shares of company stock valued at $39,946 and have sold 47,279 shares valued at $222,064. Corporate insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On Precision BioSciences

Institutional investors have recently made changes to their positions in the company. Lynx1 Capital Management LP purchased a new position in Precision BioSciences in the 4th quarter worth approximately $2,919,000. Janus Henderson Group PLC raised its stake in shares of Precision BioSciences by 10.9% in the third quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock worth $6,322,000 after purchasing an additional 68,943 shares during the last quarter. Citadel Advisors LLC raised its stake in shares of Precision BioSciences by 58.0% in the fourth quarter. Citadel Advisors LLC now owns 153,675 shares of the company’s stock worth $586,000 after purchasing an additional 56,400 shares during the last quarter. Moloney Securities Asset Management LLC lifted its holdings in shares of Precision BioSciences by 177.0% during the fourth quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock valued at $335,000 after purchasing an additional 56,100 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Precision BioSciences during the fourth quarter valued at $211,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.